Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Clin Exp Oncol Vol: 6 Issue: 1

Thromboembolic Events in Polycythaemia Vera Patients:An Audit of the Hungarian Philadelphia Negative Chronic Myeloproliferative Neoplasia Register

Péter Dombi1, Hajnalka Andrikovics2, Árpád Illés3, Judit Demeter4, Lajos Homor5, Zsófia Simon3, Miklós Udvardy3, Ádám Kellner6 and Miklós Egyed6
1St. Borbála Hospital, Tatabánya, Hungary
2Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Budapest, Hungary
3Department of Internal Medicine, University of Debrecen, Debrecen, Hungary
4Department of Internal Medicine, Semmelweis University, Budapest, Hungary
5Pázmány Péter Catholic University, Budapest, Hungary
6Department of Hematology of Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary
Corresponding author : Miklós Egyed
Department of Hematology of Somogy County Kaposi Mór Teaching Hospital Tallián Gy. str. 20-32 Kaposvár, 7400, Hungary
Tel: +36 30 9021 067
Fax: +36 82 510 076
E-mail: [email protected]
Received: November 15, 2016 Accepted: December 06, 2016 Published: December 14, 2016
Citation: Dombi P, Andrikovics H, Illés Á, Demeter J, Homor L, et al. (2016) Thromboembolic Events in Polycythaemia Vera Patients: An Audit of the Hungarian Philadelphia Negative Chronic Myeloproliferative Neoplasia Register. J Clin Exp Oncol 6:1. doi: 10.4172/2324-9110.1000173

Abstract

Objective: The Hungarian National Registry for Philadelphia chromosome negative myeloproliferative neoplasms was used to assess the clinical characteristics of Hungarian patients with polycythemia vera.

Methods: Data from 351 JAK2 V617F-positive patients diagnosed with PV were collected online from 15 haematology centres reporting clinical characteristics, therapeutic interventions, venous and arterial thromboembolic events, and myelofibrotic or leukaemic transformations. Vascular events (thromboembolic and haemorrhagic) were evaluated before and after diagnosis based upon the Landolfi risk assessment scale.

Results: TE were reported on 116 occasions (106 patients) before diagnosis and 152 occasions (102 cases) during follow-up. Compared to before diagnosis, after diagnosis frequency of major arterial events decreased from 11.7% to 2.6% (p<0.0001), and minor venous events increased from 2.0% to 14.2% (p<0.0001); there was no significant change in number of major venous events (from 6.3% to 8.8%; p=0.25) or minor arterial events (from 13.1% to 17.7%; p=0.12). Bleeding events were recorded in 6.4% of patients. Despite treatment, 42.2% of patients with prior thromboembolic events had recurrent thromboembolic complications. After diagnosis age and prior history of thromboembolic events were independent risk factors for arterial events, and white blood cells and diabetes for venous events. Hydroxyurea use in the low+moderate risk Landolfi group slightly, but not significantly, increased thromboembolic event risk (p=0.74).

Conclusions: This registry enables characterisation of patients with polycythemia vera. Data suggest the need for accuracy of diagnostic criteria and compliance with risk-adapted therapeutic guidelines.

Keywords: Polycythemia vera; Myeloproliferative neoplasms; Registry

Track Your Manuscript

Share This Page

Media Partners